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OBJECTIVES: Rheumatoid arthritis is a polygenically controlled systemic autoimmune disease. Rheumatoid
vasculitis is an important extra-articular phenotype of rheumatoid arthritis that can result in deep cutaneous
ulcers. The objective of this study was to establish a correlation between the frequency of major
histocompatibility complex class I/II alleles and killer immunoglobulin-like receptor genotypes in patients with
cutaneous rheumatoid vasculitis.
METHODS: Using the Scott & Bacon 1984 criteria to diagnose rheumatoid vasculitis and after excluding any
other causes such as diabetes, atherosclerosis, adverse drug reactions, infection, and smoking, patients who met
the criteria were selected. All of the selected rheumatoid vasculitis patients presented deep cutaneous ulcers.
Identification of the major histocompatibility complex class I/II and killer immunoglobulin-like receptor
genotypes was performed by polymerase chain reaction assays of samples collected from the 23 rheumatoid
vasculitis patients as well as from 80 controls (40 non-rheumatoid vasculitis RA control patients and 40 healthy
volunteers).
RESULTS: An association between the presence of the HLA-DRB1*1402 and HLA-DRB1*0101 alleles and
cutaneous lesions in rheumatoid vasculitis patients and a correlation between the inhibitor KIR2DL3 and the
HLA-C*0802 ligand in rheumatoid vasculitis patients were found.
CONCLUSION: An association was found between the presence of the HLA-DRB1*1402 and HLA-DRB1*0101
alleles and the development of cutaneous lesions in rheumatoid vasculitis patients. Additionally, the HLA-
C*0802 ligand protects these individuals from developing cutaneous lesions.
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Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by inflammatory polyarthritis (1,2). RA
is polygenically controlled, with contribution from the major
histocompatibility complex (MHC) (2–6). MHC class I mole-
cules are expressed on most nucleated human cells and
comprise the principal human leukocyte antigens (HLA) A, B
and C (3). MHC class II molecules are expressed on antigen-
presenting cells (APCs; B lymphocytes, macrophages, and
dendritic cells) and include mainly HLA-DR and HLA-DQ (3).
MHC class I molecule expression results in direct cytotoxicity
from CD4+CD28- T cells or natural killer (NK) cells, and
MHC class II molecule expression results in cytotoxicity via
APCs (3). The polygenic characteristics of RA, which result in
different phenotypic expressions, determine the heteroge-
neous presentation of articular destruction and extra-
articular manifestations (1,7). An important and potentially
life-threatening extra-articular manifestation of RA is rheu-
matoid vasculitis (RV), which affects the small- and medium-
sized arterial vessels of the upper and lower extremities,
peripheral nerves and occasionally other organs (8,10,11).
RV is a rare complication that may affect approximately
1–5% of RA patients and that is diagnosed by ruling out
other possible clinical conditions such as diabetes, athero-
sclerosis, adverse drug reactions, infections and neoplasms
(1,9). The HLA-DRB1 allele (B1*0401 homozygotes, in
particular) is more common in RV patients (12,13). InDOI: 10.6061/clinics/2015(06)04
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addition to genetic factors, evidence of RA biomarkers such
as CD4+CD28- T cells, which are uncommon in healthy
subjects, has been reported (14). CD4+CD28- T cells are
increased in RV patients, and the role of these cells has been
reported in arterial damage caused by inflammatory injury
(15,16). Because CD4+CD28- T cells do not express the CD40
ligand, they develop direct cytotoxic abilities and work in
conjunction with the CD57 expressed on NK cells in RV
patients, suggesting that both cells are involved in vascular
endothelial damage (17,18). Regarding NK cells, the devel-
opment of vascular damage is intrinsically dependent on the
interaction of these cells with MHC class I molecules in RA
patients (11,19). NK cells express activating and inhibiting
receptors on their surface, which interact with the MHC
antigens of vascular endothelial cells, resulting in NK cell
activation or inhibition. On the NK cell surface, killer
immunoglobulin-like receptors (KIRs), which recognize
MHC class I molecules, are present (20). Increased cell surface
expression of HLA-C ligands has been shown in RV patients.
These ligands interact with KIR2DS2, which is present on
CD4+CD28- T cells, confirming the similarity of CD4+CD28-
T cell characteristics with NK cells, as both cell types are
derived from the same hematopoietic stem cell (3,11,21).
The objective of this study was to establish a correlation
between the frequency of MHC class I/II and KIR genotypes
and cutaneous RV.
’ METHODS AND MATERIALS
Patient selection
We evaluated patients diagnosed with RA who were
followed for a period of 2 years (2012–2013) in the
Rheumatology Department at the University of Campinas
Teaching Hospital (HC-UNICAMP), a tertiary referral hospital
located in Campinas, Sao Paulo State, Brazil. The clinical data
of patients, who were all ethically unrelated, were obtained
through a review of their records. The study was approved by
the Ethics Committee, and the patients provided informed
consent. The RA diagnosis was based on the American
College of Rheumatology (ACR) 1987 Rheumatoid Arthritis
classification criteria (22). Patients under 16 years of age or
with overlap syndrome, diabetes, atherosclerosis, a history of
adverse drug reactions, infection, or a history of smoking were
excluded. RV was clinically diagnosed by the presence of deep
cutaneous ulcers (DCU) on the lower limbs, by localized pain
in areas of healthy skin that was suggestive of neuropathic
involvement of small sensory fibers or by digital infarction of
the toes (9). The diagnosis was based on the Scott & Bacon
1984 clinical criteria and required 1 of the following
3 characteristics: DCU, symptoms suggestive of mononeuritis
multiplex (MNM), or digital infarction (9,23,24). All patients
were evaluated for rheumatoid factor (RF) and citrullinated
protein antibody (anti-CCP).
Control population
Patients diagnosed with RA from the Rheumatology
Department at the HC-UNICAMP who were selected during
the period that the RV cases were analyzed were included as
controls (22). Blood donors from HC-UNICAMP were also
included as healthy patient (HP) controls. Using the RV
diagnostic criteria, some of the patients exhibiting evidence of
the condition were excluded from the control groups. In the
comparative analysis of case and control groups, factors such
as gender and age were evenly matched across all 3 groups.
Deoxyribonucleic acid (DNA) extraction
methodology
Whole blood samples were collected and subjected to
DNA extraction using the GE Healthcare Illustra Blood
GenomicPrep Mini Spin Kits in accordance with the
manufacturer’s guidelines.
MHC Class I/II Genotyping and Reading
Methodology
DNA samples were processed using the high-resolution
SSO/Luminexs. The SSO/DNA method used oligonucleo-
tide sequence-specific probes immobilized on fluorescently
encoded microspheres. HLA alleles were identified in DNA
samples amplified by polymerase chain reaction (PCR) using
hybridization probes and flow cytometry analysis. The
manufacturer’s guidelines were strictly followed for all
methodological parameters.
KIR genotyping and reading methodology
Three reactions were analyzed for KIR genotyping to
evaluate the genetic composition of exons 3–4 (group 1),
exon 5 (group 2), and exons 7–9 (group 3). DNA amplifica-
tion was performed by PCR with specific primer sequences,
and the samples were aligned using the Luminexs system.
All steps were performed in accordance with the manufac-
turer’s guidelines.
Statistical analysis
In addition to the use of graphs and one-dimensional
scatter plots, all data collected were first descriptively
analyzed by calculating various measurements and summa-
ries, including the mean, median, minimum and maximum
values, standard deviations, and absolute and relative
frequency percentages. Pearson’s chi-squared (w2) test or an
extension of Fisher’s exact test was used to compare group
profiles according to gender, class I and II allelic frequencies,
and the presence of diverse KIR genotypes (25). Analysis of
variance (ANOVA) with one fixed factor was used to
compare the age profiles of the groups (26). Because the
study was exploratory, sample calculations were not
performed due to the lack of data in the literature comparing
the allelic frequencies in all 3 groups of interest. In all
conclusions made through inferential analysis, the level of
a significance was equal to 5%. The data were compiled into
a Windows Excel 2010 table to adequately manage the
information. Statistical analyses were performed using
R statistical software version 2.15.2.
Ethical standards
This study was approved by the ethics committee of the
University of Campinas (UNICAMP) and was conducted in
accordance with the Declaration of Helsinki of 1975, which
was revised in 1983. All 103 subjects agreed to participate in
this study by reading and signing the Informed Consent
Form that was approved by the same committee.
’ RESULTS
A total of 700 RA patients were evaluated for RV over a
2-year period. Forty patients with cutaneous ulcers were
selected. None of the patients had a clinical diagnosis of
systemic vasculitis. Of the 40 patients with cutaneous ulcers,
23 were classified as having RV, including 20 (87%) women
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and 3 (13%) men. Active ulcer cutaneous biopsies were
performed in 3/23 case patients and demonstrated the
standard histopathology of vessel wall fibrinoid necrosis
with inflammatory cell infiltration and areas of occlusion
with recanalization. All 23 case patients were undergoing
treatment with Disease Modifying Anti-Rheumatic Drugs
(DMARDs) and had also used high-dose corticosteroids at
some point during the course of RV. Therapeutic doses of
antiplatelet agents were introduced in cases of toe digital
infarctions. The 40 RA control patients were also treated with
DMARDs and occasional low doses of corticosteroids.
Of the 103 patients studied, 40 (38.8%) were in the HP
control group, 40 (38.8%) were in the RA control group, and
23 (22.4%) were in the RV case group. The age and gender
distributions of the groups are displayed in Table 1.
Notably, when comparing the gender and age profiles of
the 3 groups, these groups are statistically equivalent with
respect to gender (p=0.611) and age (p=0.927).
The frequency of class I alleles varied between 0.0% and
47.5% in the HP group, between 0.0% and 45.0% in the RA
group, and between 0.0% and 43.5% in the RV group. The
high frequencies of expression in all 3 groups can be
explained by the presence of the A*0201 allele (p=0.949),
which was observed in all evaluated patient groups.
The alleles with significantly different A*2601 (p=0.017)
and B*3906 (p=0.048) frequencies were more commonly
observed in the RV group than in the HP and RA groups.
The B*5001 (p=0.024) and C*0602 (p=0.001) alleles were more
frequently observed in the HP group than in the RA and RV
groups. The B*1501 (p=0.048) and C*1502 (p=0.027) alleles
were more frequently observed in the RA group than in the
other two groups. With respect to the C*0802 (p=0.019) allele,
it was less frequently observed in the RA group than in the
HP and RV groups. In the HP and RV groups, there was a
trend towards more frequent expression of the B*1402 allele
(p=0.057) and less frequent expression of the C*0501 allele
(p=0.056) compared with the RA group. The other alleles
were observed equally in all 3 groups, without significant
differences. These data are displayed in Table 2.
Higher allelic frequencies were observed for HLA-
DRB1*0701 (p=0.428) and DQB1*0302 (p=0.740) in the HP
group, DQB1*0301 (p=0.752) in the RA group, and
DQB1*0501 (p=0.480) in the HP and RA groups. The
comparison of class II allelic frequencies between the groups
suggests that almost all alleles were observed equally across
the groups. The only exception was the DRB1*1402 allele
(p=0.048), which was found more frequently in the RV group
than in the HP and RA groups. A trend towards a higher
frequency of the DRB1*0101 (p=0.053) allele was found in the
RV group compared with the HP and RA groups, as well as a
higher frequency of the DRB1*1503 (p=0.075) allele in the HP
group compared with the RA and RV groups. The other
alleles were equally observed in the 3 groups, without
significant differences. These data are displayed in Table 3.
Higher frequencies were observed for the KIR2DL2
genotype (p=0.529) in the RA and RV groups, as well as
for the KIR3DL2 and 3DL3 genotypes in all 3 groups
(a p-value could not be calculated). Higher frequencies were
Table 1 - General characteristics of the individuals in each group.
HP (n=40) RA (n=40) RV (n=23) Total (n=103) p-value
Gender
Female 31 77.5% 31 77.5% 20 87.0% 82 79.6% 0.611a
Male 9 22.5% 9 22.5% 3 13.0% 21 20.4%
Age (years)
Average 54.3 54.8 55.5 54.8 0.927b
Median 56.0 56.0 56.0 56.0
Minimum-maximum 25.0–77.0 17.0–78.0 32.0–71.0 17.0–78.0
Standard deviation 12.3 12.9 9.5 11.9
a Pearson’s chi-squared test, bANOVA with 1 fixed factor
Table 2 - Distribution of the HLA-A/B/C allelic frequencies among the patient groups.
HP (n=40) RA (n=40) RV (n=23) Total (n=103) p-value
A*2601 - 40 100.0% 38 95.0% 19 82.6% 97 94.2% 0.017c
+ 0 0% 2 5.0% 4 17.4% 6 5.8%
B*1402 - 36 90.0% 40 100.0% 20 87.0% 96 93.2% 0.057c
+ 4 10.0% 0 0% 3 13.0% 7 6.8%
B*1501 - 40 100.0% 35 87.5% 22 95.7% 97 94.2% 0.048c
+ 0 0% 5 12.5% 1 4.3% 6 5.8%
B*3906 - 40 100.0% 40 100.0% 21 91.3% 101 98.1% 0.048c
+ 0 0% 0 0% 2 8.7% 2 1.9%
B*5001 - 35 87.5% 40 100.0% 23 100.0% 98 95.1% 0.024c
+ 5 12.5% 0 0% 0 0% 5 4.9%
C*0501 - 37 92.5% 33 82.5% 23 100.0% 93 90.3% 0.056c
+ 3 7.5% 7 17.5% 0 0% 10 9.7%
C*0602 - 27 67.5% 38 95.0% 22 95.7% 87 84.5% 0.001a
+ 13 32.5% 2 5.0% 1 4.3% 16 15.5%
C*0802 - 35 87.5% 40 100.0% 19 82.6% 94 91.3% 0.019c
+ 5 12.5% 0 0% 4 17.4% 9 8.7%
C*1502 - 38 95.0% 31 77.5% 22 95.7% 91 88.3% 0.027c
+ 2 5.0% 9 22.5% 1 4.3% 12 11.7%
aPearson’s chi-squared test, cextension of Fisher’s exact test, absent (-), present (+)
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observed for the KIR3DP1 genotype (p40.999) only in the
RV group. The various KIR genotypes showed comparable
frequencies in all 3 groups; however, some trends suggested
a higher frequency of 2DL3 in the HP and RV groups than in
the RA group (p=0.096). A trend towards more frequent
expression of 2DL5 was observed in the HP group compared
with the RA and RV groups (p=0.064). Finally, a trend
indicating higher frequencies of 3DL1 was observed in the
HP group compared with the RA and RV groups (p=0.060).
The other genotypes were equally observed in the 3 groups,
without significant differences. These data are displayed in
Table 4.
’ DISCUSSION
Our study evaluated the frequencies of HLA class I and II
alleles in 23 RV patients compared with HPs and RA patients
without RV. KIR genotyping was performed in these groups,
which was correlated with HLA class I antigens. This is the
first work to perform correlation genotyping of HLA class I/
KIR antigens in Brazilian RV patients. Studies concerning
HLA class I/KIR in RV patients are relevant from an
etiopathogenic standpoint as an effort to identify patients
with a severe disease.
Watts et al. described an annual RV incidence of 12.5 per
million people (95% CI=8.5–17.2), with 15.8 per million (95%
CI=9.5–24.7) men and 9.4 per million (95% CI=4.8–16.4)
women (27). Alternatively, Symmons et al. found an annual
incidence of 140 per million men and 360 per million women
with RV in a similar population (28). RV affects approxi-
mately 1–5% of RA patients, which emphasizes the relative
rarity of RV (1,9). We found 23 RV patients in a population of
700 RA patients over a period of 2 years, which was
equivalent to a rate of 3.3%. Our findings are similar to
previously reported studies.
RV typically presents in patients who have suffered from
rheumatoid arthritis for more than 10 years (1,9). In this
study, the average age in the RV group was 55.5 years, which
is comparable to the global general RA patient population.
RV was more frequent in females (87.0%), but this gender
predominance is not different from that of general RA
patients without RV (1,9). In contrast to the findings of this
study, gender has been reported to influence the disease
phenotype, leading to more severe articular destruction and
extra-articular manifestations, including RV, in men (29).
Cutaneous biopsies were performed on 3 patients with a
confirmed RV diagnosis. In the remaining 20 patients, RV
was diagnosed according to the Scott & Bacon clinical criteria
because all patients had a previous RA diagnosis and all
other causes of vasculopathy were excluded (9,22–24,30).
Before comparing significant allelic frequencies or analyz-
ing statistical trends between groups for MHC class I and II
antigens or KIRs, understanding the behavior of these alleles
in the population studied was necessary. This was accom-
plished using the Allele Frequency Net Database (AFND) to
evaluate whether any associations that existed between the
alleles examined could under- or overestimate the frequency
of each allele in a particular geographic region of the
population studied (31). When the search tool on the AFND
site was utilized, no data on class I alleles were found for the
Campinas region in Sao Paulo, Brazil. For the class II alleles,
the same search tool was used for the region of Campinas,
and data were found for the DRB1*0101, DRB1*0102,
DRB1*1402 and DRB1*1502 alleles. Similarly, no association
of these alleles with other alleles was found in this
geographic region.
After confirming the allelic frequencies, their correlations
with KIR frequency findings were analyzed. KIR2DL3 is an
inhibitor that interacts with HLA-C (C*01, C*03, C*07, C*08,
C*12, C*13, C*14 and C*16) ligands (32). KIR2DL5 is also an
inhibitor, but its interactions with MHC class I molecules
remain controversial (32). Therefore, correlating the fre-
quency of KIR2DL5 with the findings from this class was not
possible. KIR3DL1 is an inhibitor that interacts with HLA-A
and HLA-B (A*24, B*13, B*27, B*37, B*44, B*51, B*52, B*53,
B*57 and B*58) ligands (32). Nonetheless, the interaction of
KIR2DL3 with the C*0802 ligand can disable the missing-self
response; thus, in our RV patient population, C*0802 could
be a protective allele against the development of cutaneous
lesions from direct cytotoxicity (NK cells or CD4+CD28- T
Table 3 - Distribution of HLA-DRB1 allelic frequencies among the patient groups.
HP (n=40) RA (n=40) RV (n=23) Total (n=103) p-value
*0101 - 37 92.5% 34 85.0% 16 69.6% 87 84.5% 0.053a
+ 3 7.5% 6 15.0% 7 30.4% 16 15.5%
*0102 - 36 90.0% 40 100.0% 20 87.0% 96 93.2% 0.057c
+ 4 10.0% 0 0% 3 13.0% 7 6.8%
*1402 - 40 100.0% 40 100.0% 21 91.3% 101 98.1% 0.048c
+ 0 0% 0 0% 2 8.7% 2 1.9%
*1503 - 36 90.0% 40 100.0% 23 100% 99 96.1% 0.075c
+ 4 10.0% 0 0% 0 0% 4 3.9%
aPearson’s chi-squared test, c extension of Fisher’s exact test, absent (-), present (+)
Table 4 - Distribution of KIR genotypes among the patient groups.
HP (n=40) RA (n=40) RV (n=23) Total (n=103) p-value
2DL3 - 5 12.5% 12 30.0% 3 13.0% 20 19.4% 0.096a
+ 35 87.5% 28 70.0% 20 87.0% 83 80.6%
2DL5 - 11 27.5% 20 50.0% 12 52.2% 43 41.7% 0.064a
+ 29 72.5% 20 50.0% 11 47.8% 60 58.3%
3DL1 - 7 17.5% 1 2.5% 1 4.3% 9 8.7% 0.060c
+ 33 82.5% 39 97.5% 22 95.7% 94 91.3%
aPearson’s chi-squared test, c extension of Fisher’s exact test, absent (-), present (+)
411
CLINICS 2015;70(6):408-412 KIR2DL3/HLA-C*0802 in Brazilian patients
Nishimura WE et al.
cells). This finding contradicts the results of other studies
(11,19,21,33, 34).
Regarding the frequency results for class II alleles in the RV
group, the frequency of DRB1*1402 (8.7%) was significantly
different, and a statistical trend towards a difference in
DRB1*0101 (30.4%) was observed compared with the other
groups. Similarly to the findings of other studies (12,13), these
findings suggest that these alleles are associated with the
development of cutaneous lesions in our RV patient population
because they are associated with APCs (B lymphocytes,
macrophages and dendritic cells). For the DRB1*1503 allele
(10.0%), a statistical trend towards a higher frequency was
found in the HP group; this allele could be considered
protective against RA and RV in our population.
An association exists between the presence of MHC class II
alleles (HLA-DRB1*1402 and HLA-DRB1*0101) and the devel-
opment of cutaneous lesions in RV patients. In other words, an
association exists between APCs and vascular damage. The
KIR2DL3 inhibitor was frequently found in RV patients, and its
interaction with the HLA-C*0802 ligand suggests that this allele
protects these individuals from cutaneous lesions caused by
direct cytotoxicity. Our findings have not been previously
described. Despite the rarity of RV, this study could be
considered a baseline study for new genetic and multicenter
descriptive studies to better our understanding of the
phenotypic expression of this disease in Brazil.
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